#idweek2025 new in #UTI IDSA vs wikiguidelines #idsky #Idfellows #idfellowship #teachID

#idweek2025 new in #UTI IDSA vs wikiguidelines 2/ #idsky

#idweek2025 new in #UTI IDSA (GRADE methodology: clinical cure critical based on pt feedback) vs wikiguidelines (clear recommendation vs clinical review) 1/

Don’t miss @bwtrautner.bsky.social and I talk about what’s new in UTI (the UTI WikiGuideline and IDSA cUTI guideline) on Wednesday AM at 08:00 EST! #idweek2025 #idsky

Don’t miss @bwtrautner.bsky.social and I talk about what’s new in UTI (the UTI WikiGuideline and IDSA cUTI guideline) on Wednesday AM at 08:00 EST! #idweek2025 #idsky

#COVID patients who don't receive remdesivir not more likely to die, data suggest

Models found no difference in all-cause death rates, 30-day hospital readmissions, or length of stay before and after restrictions were put into place.

www.cidrap.umn.edu/c...

In CID: Our real world study is the 1st (to our knowledge) to detail widespread restriction of remdesivir with patients that represent present-day epidemiology in the era of near universal SARS-CoV-2 seropositivity.

#IDSky
#MedSky
@ebhirsch.bsky.social

academic.oup.com/cid/advance-...

In CID: Our real world study is the 1st (to our knowledge) to detail widespread restriction of remdesivir with patients that represent present-day epidemiology in the era of near universal SARS-CoV-2 seropositivity.

#IDSky
#MedSky
@ebhirsch.bsky.social

academic.oup.com/cid/advance-...

We are incredibly proud of our entire UTI WikiGuideline drafting team!

#IDSky: the iDIAPASON trial was stopped early due to low enrollment, results still published, sheds doubt on whether the 3 RCTs demonstrating non-inferiority of 8 days to 15 days for VAP is applicable to PA-VAP -- pulmonologists are quoting this study still!

How long do you typically treat PA-VAP?

WOW 🔥
Our article is still on the most viewed list in the last 7 days from #JAMANetworkOpen
@zacrobid.bsky.social
@dremilymcd.bsky.social @drtoddlee.bsky.social @bradspellberg.bsky.social #idsky #medsky #utisky #EMIMCC

45 year old generally healthy female on infliximab for Crohn's disease develops non-typhoidal Salmonella bacteremia and UC+ for same organism. She rapidly improves on IV ceftriaxone.

Q: What duration are you treating for?

A:
-- 7 days?
-- 10 days?
-- 14 days?
-- 4-6 weeks?

And... why, #IDSky?!

45 year old generally healthy female on infliximab for Crohn's disease develops non-typhoidal Salmonella bacteremia and UC+ for same organism. She rapidly improves on IV ceftriaxone.

Q: What duration are you treating for?

A:
-- 7 days?
-- 10 days?
-- 14 days?
-- 4-6 weeks?

And... why, #IDSky?!

What did I do this morning? Fill out quick surveys about CDI! They’re quick and support very important research! #IDSky

redcap.link/guubtkxs

@connorprosty.bsky.social @drtoddlee.bsky.social @dremilymcd.bsky.social

My first #IDSky post will be a shameless promotion of our new UTI WikiGuideline!

jamanetwork.com/journals/jam...

Of 37 questions, only 6 had enough data to fully meet criteria for a clear recommendation!